Latest Instil Bio News & Updates

See the latest news and media coverage for Instil Bio. We track all announcements, press releases, and industry mentions in real time, all in one place.

Instil Bio

Biotechnology company advancing innovative therapeutic opportunities

instilbio.com

Company type: Public company
Number of employees: 10–60

Last updated Today

Latest news about Instil Bio

In short: Instil Bio terminated its oncology licensing agreement with ImmuneOnco and reported a cash position of $74.7 million in early 2026.

Company announcements

May 15 Instil Bio

Instil Bio reports Q1 2026 financial results and corporate update

Cash position of $74.7 million expected to fund operations beyond 2027; actively evaluating acquisitions and in-licensing.

March 27 Instil Bio

Instil Bio reports Q4 and full year 2025 financial results

Company evaluating acquisitions and in-licensing; $76.3M cash expected to fund operations beyond 2027.

January 6 Instil Bio

Instil Bio discontinues AXN-2510 and ends ImmuneOnco collaboration

Under the termination, rights revert to ImmuneOnco, and Axion winds down clinical development of AXN-2510, an investigational therapy.

Media coverage

May 23 The Globe and Mail

Instil Bio Ends Key Oncology Licensing Agreement with ImmuneOnco

Instil Bio ( (TIL)) has shared an update. On January 5, 2026, Instil Bio’s subsidiary Axion Bio and ImmuneOnco Biopharmaceuticals mutually terminated their August 1...

25 December 2025 Fierce Biotech

Instil Bio takes the ax to its lead asset, cutting 60% of its staff in the process

Instil Bio is calling it quits on its lead tumor-infiltrating lymphocyte therapy and four corresponding programs, a major overhaul of the company's priorities that's resulting...

25 May 2025 Yahoo Finance

Wall Street Analysts Believe Instil Bio (TIL) Could Rally 343.63%: Here s is How to Trade

The consensus price target hints at a 343.6% upside potential for Instil Bio (TIL). While empirical...

25 May 2025 Nasdaq

Instil Bio Announces FDA Clearance for IND of AXN-2510, Phase 1 Trial Expected by End of 2025

Instil Bio, Inc. announced the clearance of an Investigational New Drug (IND) application for its drug AXN-2510 by the FDA, enabling the company to begin...

Never miss news about Instil Bio

Track Instil Bio and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Instil Bio competitors & trending companies

Browse news for competitors to Instil Bio and other trending companies.